Total Payments
$12,316
2024 Payments
$170.86
Companies
14
Transactions
58
Medicare Patients
2,861
Medicare Billing
$334,603
Payment Breakdown by Category
Research$7,684 (62.4%)
Travel$3,042 (24.7%)
Food & Beverage$1,440 (11.7%)
Education$149.86 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,684 | 11 | 62.4% |
| Travel and Lodging | $3,042 | 11 | 24.7% |
| Food and Beverage | $1,440 | 33 | 11.7% |
| Education | $149.86 | 3 | 1.2% |
Payments by Type
Research
$7,684
11 transactions
General
$4,632
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $5,005 | 3 | $0 (2018) |
| INTUITIVE SURGICAL, INC. | $3,583 | 29 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,679 | 8 | $0 (2021) |
| GlaxoSmithKline, LLC. | $185.78 | 2 | $0 (2023) |
| TESARO, Inc. | $171.07 | 4 | $0 (2019) |
| Foundation Medicine, Inc. | $129.93 | 2 | $0 (2023) |
| Gen-Probe Sales & Service, Inc. | $122.00 | 1 | $0 (2022) |
| Baxter Healthcare | $109.13 | 3 | $0 (2023) |
| Seagen Inc. | $96.00 | 1 | $0 (2023) |
| Genentech USA, Inc. | $90.69 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170.86 | 7 | INTUITIVE SURGICAL, INC. ($170.86) |
| 2023 | $616.88 | 10 | Foundation Medicine, Inc. ($129.93) |
| 2022 | $246.03 | 3 | Gen-Probe Sales & Service, Inc. ($122.00) |
| 2021 | $2,154 | 7 | F. Hoffmann-La Roche AG ($2,137) |
| 2020 | $623.37 | 5 | F. Hoffmann-La Roche AG ($541.83) |
| 2019 | $179.99 | 7 | Intuitive Surgical, Inc. ($165.49) |
| 2018 | $8,077 | 15 | Merck Sharp & Dohme Corporation ($5,005) |
| 2017 | $247.61 | 4 | TESARO, Inc. ($120.00) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $6.00 | General |
| Category: SURGERY | ||||||
| 12/03/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: SURGERY | ||||||
| 11/12/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $71.37 | General |
| Category: SURGERY | ||||||
| 09/17/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $52.63 | General |
| Category: SURGERY | ||||||
| 08/06/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $25.86 | General |
| Category: SURGERY | ||||||
| 08/06/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: SURGERY | ||||||
| 07/09/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $4.25 | General |
| Category: SURGERY | ||||||
| 11/16/2023 | Myriad Genetic Laboratories, Inc. | MYCHOICE CDX (Device) | Food and Beverage | In-kind items and services | $79.67 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $92.55 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Oncology | ||||||
| 07/21/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $10.41 | General |
| 06/06/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $74.09 | General |
| Category: SURGERY | ||||||
| 05/25/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $119.52 | General |
| 04/27/2023 | Baxter Healthcare | TISSEEL (Device) | Food and Beverage | In-kind items and services | $58.33 | General |
| Category: Surgical Care | ||||||
| 04/13/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $96.00 | General |
| Category: Oncology | ||||||
| 03/14/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $38.12 | General |
| Category: SURGERY | ||||||
| 01/16/2023 | Baxter Healthcare | FLOSEAL (Device) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Surgical Care | ||||||
| 10/20/2022 | Baxter Healthcare | ADEPT (Device) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: Surgical Care | ||||||
| 08/25/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $93.23 | General |
| Category: ONCOLOGY | ||||||
| 04/14/2022 | Gen-Probe Sales & Service, Inc. | APTIMA (Device) | Food and Beverage | In-kind items and services | $122.00 | General |
| Category: Diagnostics | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $630.78 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $434.20 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $426.64 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $254.13 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $206.85 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer | Merck Sharp & Dohme Corporation | $5,005 | 3 |
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $2,310 | 7 |
| A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | F. Hoffmann-La Roche AG | $369.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 546 | 5,221 | $418,086 | $61,699 |
| 2022 | 26 | 781 | 24,004 | $912,336 | $105,467 |
| 2021 | 21 | 701 | 10,130 | $495,802 | $82,527 |
| 2020 | 28 | 833 | 21,911 | $679,508 | $84,910 |
Total Patients
2,861
Total Services
61,266
Medicare Billing
$334,603
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 4 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2020 | 22 | 70 | $23,380 | $3,749 | 16.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2020 | 55 | 255 | $15,810 | $2,656 | 16.8% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2020 | 24 | 710 | $86,620 | $2,426 | 2.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $9,435 | $2,400 | 25.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 52 | 272 | $9,520 | $2,085 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 23 | $7,590 | $1,901 | 25.0% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2020 | 20 | 79 | $12,324 | $1,879 | 15.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 12 | 13 | $5,733 | $1,508 | 26.3% |
| 71260 | Ct scan chest with contrast | Office | 2020 | 18 | 27 | $21,519 | $1,362 | 6.3% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 33 | 109 | $11,445 | $1,357 | 11.9% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2020 | 16 | 10,512 | $21,024 | $1,255 | 6.0% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2020 | 20 | 558 | $167,400 | $1,239 | 0.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 74 | 293 | $5,567 | $866.67 | 15.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 13 | 13 | $1,768 | $396.38 | 22.4% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2020 | 18 | 2,700 | $8,100 | $236.83 | 2.9% |
| 80048 | Blood test, basic group of blood chemicals | Office | 2020 | 12 | 13 | $624.00 | $109.13 | 17.5% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2020 | 14 | 43 | $817.00 | $85.97 | 10.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 23 | 710 | $710.00 | $68.60 | 9.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2020 | 22 | 57 | $280.00 | $34.21 | 12.2% |
| J3490 | Unclassified drugs | Office | 2020 | 17 | 45 | $405.00 | $29.33 | 7.2% |
About Dr. Charles Anderson, M.D
Dr. Charles Anderson, M.D is a Obstetrics & Gynecology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1215191259.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Anderson, M.D has received a total of $12,316 in payments from pharmaceutical and medical device companies, with $170.86 received in 2024. These payments were reported across 58 transactions from 14 companies. The most common payment nature is "" ($7,684).
As a Medicare-enrolled provider, Anderson has provided services to 2,861 Medicare beneficiaries, totaling 61,266 services with total Medicare billing of $334,603. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Eugene, OR
- Active Since 07/17/2008
- Last Updated 08/05/2021
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1215191259
Products in Payments
- KEYTRUDA (Biological) $5,005
- Da Vinci Surgical System (Device) $3,583
- TECENTRIQ (Biological) $2,137
- Tecentriq (Biological) $541.83
- ZEJULA (Drug) $264.30
- APTIMA (Device) $122.00
- TIVDAK (Biological) $96.00
- JEMPERLI (Biological) $92.55
- Avastin (Biological) $90.69
- MYCHOICE CDX (Device) $79.67
- TISSEEL (Device) $58.33
- ADEPT (Device) $30.80
- Xtandi (Drug) $28.19
- FLOSEAL (Device) $20.00
- LYNPARZA (Drug) $16.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Eugene
Amy Mccarthy, Md, MD
Obstetrics & Gynecology — Payments: $6,796
Obstetrics & Gynecology $6,796
Dr. Elizabeth Mccorkle, Md, MD
Obstetrics & Gynecology — Payments: $6,034
Obstetrics & Gynecology $6,034
Dr. Johanna Higdon, Md, MD
Obstetrics & Gynecology — Payments: $4,776
Obstetrics & Gynecology $4,776
Richard Lee, Md, MD
Obstetrics & Gynecology — Payments: $1,244
Obstetrics & Gynecology $1,244
Brian Wakefield, M.d, M.D
Obstetrics & Gynecology — Payments: $1,142
Obstetrics & Gynecology $1,142
Dr. Sara Gerhards, Md, MD
Obstetrics & Gynecology — Payments: $1,119
Obstetrics & Gynecology $1,119